Search
Amylyx Pharmaceuticals Inc
AMLXAdd to Watchlist
17.950USD
-0.010-0.06%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.99BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.06%
5 Days
+5.59%
1 Month
+27.58%
6 Months
+48.59%
Year to Date
+48.59%
1 Year
+180.03%
Key Figures
17.840Open
18.050High
1.80MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.62%Turnover Ratio
17.960Prev. Close
17.378Low
26.26MTurnover
LossP/E Static
7.30P/B
0.00%Div Yield TTM
-58.49%ROA
18.60552wk High
0.65Volume Ratio
-301.74MNet Profit
111.03MShares
-1.4849EPS TTM
-0.15Beta
-63.26%ROE
4.70552wk Low
3.74%Amplitude
63.22%Gross Margin
1.99BMarket Cap
9.24Reward/Risk
3.80%Risk Rate
TradingKey Stock Score of Amylyx Pharmaceuticals Inc
Currency: USD Updated: 2026-07-01Key Insights
Amylyx Pharmaceuticals Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 49 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 24.40.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Amylyx Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Amylyx Pharmaceuticals Inc Highlights
StrengthsRisks
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
Undervalued
The company’s latest PE is -12.09, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 115.74M shares, decreasing 6.89% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 59.82K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.30.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
24.400
Target Price
+35.86%
Upside Space
Amylyx Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Amylyx Pharmaceuticals Inc Info
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
Ticker SymbolAMLX
CompanyAmylyx Pharmaceuticals Inc
CEOKlee (Justin)
Websitehttps://www.amylyx.com/
Related Instruments
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52358.200
+103.900 (+0.20%)
29957.400
+158.100 (+0.53%)
7499.800
+24.300 (+0.33%)
14988.000
-367.000 (-2.39%)
69819.000
+334.000 (+0.48%)
6298.200
+22.800 (+0.36%)
67.661
-0.307 (-0.45%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4055.170
+24.400 (+0.60%)
FAQs
What is the current price of Amylyx Pharmaceuticals Inc (AMLX)?
The current price of Amylyx Pharmaceuticals Inc (AMLX) is 17.95.
What is the symbol of Amylyx Pharmaceuticals Inc?
The ticker symbol of Amylyx Pharmaceuticals Inc is AMLX.
What is the 52-week high of Amylyx Pharmaceuticals Inc?
The 52-week high of Amylyx Pharmaceuticals Inc is 18.61.
What is the 52-week low of Amylyx Pharmaceuticals Inc?
The 52-week low of Amylyx Pharmaceuticals Inc is 4.71.
What is the market capitalization of Amylyx Pharmaceuticals Inc?
The market capitalization of Amylyx Pharmaceuticals Inc is 1.99B.
Is Amylyx Pharmaceuticals Inc (AMLX) currently rated as Buy, Hold, or Sell?
According to analysts, Amylyx Pharmaceuticals Inc (AMLX) has an overall rating of Buy, with a price target of 24.40.
What is the Earnings Per Share (EPS TTM) of Amylyx Pharmaceuticals Inc (AMLX)?
The Earnings Per Share (EPS TTM) of Amylyx Pharmaceuticals Inc (AMLX) is -1.53.